To Study Different Levels of MK0493 for Safety, Efficacy, and Tolerability in Obese Patients (0493-017)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Obesity

Treatments: Drug: MK0493

Study type: Interventional

Funder types: Industry

Identifiers

NCT00482196

2007_577

0493-017

Details and patient eligibility

About

To study different doses of MK0493 for safety, efficacy and tolerability in obese patients.

Enrollment: 173 patients

Sex: All

Ages: 21 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient is between 21 and 65 years of age

Exclusion criteria

• HIV positive as determined by medical history
• Patient is pregnant, lactating or plans to become pregnant
• Patient has undergone surgical treatment for obesity
• Patient has undergone a surgical procedure within 4 weeks prior to Visit 1 or plans to undergo a surgical procedure during the study
• Patient plans to consume more than 2 glasses of grapefruit juice per day during the study
• Patient has participated in another clinical study (involving an investigational drug) within 3 months prior to restudy screening

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind